Grace Therapeutics, Inc.
GRCE
$3.16
$0.020.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.15% | 37.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.16% | -2.86% | |||
| Operating Income | 18.16% | 2.86% | |||
| Income Before Tax | 72.10% | -780.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 72.10% | -628.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.10% | -628.62% | |||
| EBIT | 18.16% | 2.86% | |||
| EBITDA | 18.10% | 2.86% | |||
| EPS Basic | 72.10% | -558.91% | |||
| Normalized Basic EPS | 72.12% | -667.44% | |||
| EPS Diluted | 72.10% | -558.91% | |||
| Normalized Diluted EPS | 72.12% | -667.44% | |||
| Average Basic Shares Outstanding | 0.00% | 15.14% | |||
| Average Diluted Shares Outstanding | 0.00% | 15.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||